Beone eyes Huahui Health’s trispecific HH-160 with $2B option deal

May 4, 2026

Beone Medicines Ltd. gained an exclusive option to develop cancer immunotherapy HH-160 worldwide in a deal potentially worth more than $2 billion for Huahui Health Ltd., the developer of the trispecific antibody.

BioWorld Science Deals and M&A Cancer Antibody Asia-Pacific China U.S.

University of Western Australia patents 5-HT2A/B modulators

BioWorld Science

University of Western Australia has identified new lysergic acid diethylamide (LSD) analogues acting as 5-HT2A and 5-HT2B modulators reported to be useful for the...

Alceptor Therapeutics discovers new α2B-adrenoceptor agonists

BioWorld Science

Alceptor Therapeutics Inc. has patented new pyrazol-5-amine α2B-adrenoceptor agonists reported to be useful for the treatment of pain and hypertension.

Glucagon-like peptide-1 receptor (GLP-1R) complex

Quintuple GLP-1–GIP–PPAR agonist for obesity and diabetes control

BioWorld

A new molecule combines the action of two incretins, GLP-1 and GIP, hormones that regulate glucose and appetite, with lanifibranor, a triple agonist of peroxisome...

EQ-504 is AhR agonist for ulcerative colitis, related disorders

BioWorld Science

Activating the aryl hydrocarbon receptor (AhR) in immune cells enhances anti-inflammatory pathways and limits pathogenic immune responses. Equillium Inc. has...

Beijing Innocare Pharma Tech discloses new GSPT1 degradation inducers

BioWorld Science

Beijing Innocare Pharma Tech Co. Ltd. has synthesized new antibody-drug conjugates comprising antibody or antigen-binding fragment covalently linked to eukaryotic...